Analysis of p16 gene mutations and deletions in childhood acute lymphoblastic leukemias
Keywords:
Acute, Lymphoblastic, Leukemia, Tumor, Suppressor, Gene, p16Abstract
CONTEXT: The p16 tumor suppressor gene encodes a cyclin-dependent kinase 4 inhibitor that blocks cell division during the G1 phase of the cell cycle. Alterations in this gene have been reported for various neoplasia types, including acute lymphoblastic leukemias (ALL), especially T-cell acute lymphoblastic leukemias (ALL). OBJECTIVE: To determine probable alterations in the p16 gene in children with acute lymphoblastic leukemias using the polymerase chain reaction (PCR) and direct DNA sequencing and also to analyze event-free survival (EFS). DESIGN: Retrospective study. SETTING: Department of Child Care and Pediatrics, Faculty of Medicine of Ribeirão Preto, Universidade Federal de São Paulo. PARTICIPANTS: Fifty-six children with ALL (mean age 4 years). Forty (71.43%) had B-cell and 12 (21.43%) had T-cell ALL; 4 (7.1%) were biphenotypic. SAMPLE: DNA samples were extracted from bone marrow upon diagnosis and/or relapse. In 2 T-cell cases, DNA from cerebrospinal fluid (CSF) was analyzed. MAIN MEASUREMENTS: Deletions or nucleotide substitutions in exons 1, 2 and 3 of the p16 gene were determined by PCR and nucleotide sequencing. Event-free survival was determined by the Kaplan-Meyer and log-rank test for patients carrying normal and altered p16. RESULTS: Deletions in exon 3 were observed in five cases. Abnormal migration in PCR was observed in seven cases for exon 1, six for exon 2, and five for exon 3. Mutations in exon 1 were confirmed by direct DNA sequencing in four cases and in exon 2 in two cases. The Kaplan-Meyer survival curves and the log-rank test showed no significant differences in 5-year EFS between children with normal or altered p16, or between patients with BALL carrying normal or altered p16 gene. Patients with T-ALL could not be evaluated via Kaplan-Meier due to the small number of cases. CONCLUSIONS: Our results, particularly regarding deletion frequency, agree with others suggesting that deletions in the p16 are initial events in leukemia genesis. The small number of samples did not allow stablishment of correlation between childhood ALL and the p16 point mutations found in our study. Kaplan-Meier analysis revealed no significant correlation between EFS and alterations in ALL. The p16 alterations frequency observed for B and TALL agreed with reports from other centers.
Downloads
References
Grandér D. How do mutated oncogenes and tumor suppressor genes cause cancer? Med Oncol 1998;15(1):20-6.
Hunter T, Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 1994;79(4):573-82.
Schafer KA. The cell cycle: a review. Vet Pathol 1998;35(6):461-78.
Hannon GJ, Beach D. p15INK4B is a potential effector of TGF- beta-induced cell cycle arrest. Nature 1994;371(6494):257-61.
Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366(6456):704-7.
Caldas C, Hahn SA, da Costa LT, et al. Frequent somatic muta- tions and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994;8(1):27-32.
Cairns P, Mao L, Merlo A, et al. Rates of p16 (MTS1) muta- tions in primary tumors with 9p loss. Science 1994;265(5170):415-7.
Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994;368(6473):753-6.
Guo SX, Taki T, Ohnishi H, et al. Hypermethylation of p16 and p15 genes and RB protein expression in acute leukemia. Leuk Res 2000;24(1):39-46.
Yamada Y, Hatta Y, Murata K, et al. Deletions of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia. J Clin Oncol 1997;15(5):1778-85.
Fizzotti M, Cimino G, Pisegna S, et al. Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. Blood 1995;85(10):2685-90.
Diccianni MB, Batova A, Yu J, et al. Shortened survival after relapse in T-cell acute lymphoblastic leukemia patients with p16/ p15 deletions. Leuk Res 1997;21(6):549-58.
Carter TL, Reaman GH, Kees UR. INK4A/ARF deletions are acquired at relapse in childhood acute lymphoblastic leukemia: a paired study on 25 patients using real-time polymerase chain reaction. Br J Haematol 2001;113(2):323-8.
Kees UR, Ranford PR, Hatzis M. Deletions of the p16 gene in pediatric leukemia and corresponding cell lines. Oncogene 1996;12(10):2235-9.
Maloney KW, McGavran L, Odom LF, Hunger SP. Acquisition of p16(INK4A) and p15(INK4B) gene abnormalities between initial diagnosis and relapse in children with acute lymphoblas- tic leukemia. Blood 1999;93(7):2380-5.
Ohnishi H, Hanada R, Horibe K, et al. Homozygous deletions of p16/MTS1 and p15/MTS2 genes are frequent in t (1;19)- negative but not in t (1;19)-positive B precursor acute lymphob- lastic leukemia in childhood. Leukemia 1996;10(7):1104-10.
Rasool O, Heyman M, Brandter LB, et al. p15ink4B and p16ink4 gene inactivation in acute lymphocytic leukemia. Blood 1995;85(12):3431-6.
Otsuki T, Clark HM, Wellman A, Jaffe ES, Raffeld M. Involve- ment of CDKN2 (p16 INK4A/MTS1) and p15INK4B/MTS2 in human leukemias and lymphomas. Cancer Res 1995;55(7):1436-40.
Stranks G, Height SE, Mitchell P, et al. Deletions and rearrangements of CDKN2 in lymphoid malignancy. Blood 1995;85(4):893-901.
Okuda T, Shurtleff SA, Valentine MB, et al. Frequent deletion of p16INK4a/MTS1 and p15INK4b/MTS2 in pediatric acute lymphoblastic leukemia. Blood 1995;85(9):2321-30.
Haidar MA, Cao XB, Manshouri T, et al. p16INK4A and p15INK4B gene deletions in primary leukemias. Blood 1995;86(1):311-5.
Takeuchi S, Bartram CR, Seriu T, et al. Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/ MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. Blood 1995;86(2):755-60.
Delmer A, Tang R, Senamaud-Beaufort C, Paterlini P, Brechot C, Zittoun R. Alterations of cyclin-dependent kinase 4 inhibi- tor (p16 INK4A/MTS1) gene structure and expression in acute lymphoblastic leukemias. Leukemia 1995;9(7):1240-5.
Iolascon A, Faienza MF, Coppola B, della Ragione F, Schettini F, Biondi A. Homozygous deletions of cyclin-dependent kinase in- hibitor genes, p16(INK4A) and p18, in childhood T cell lineage acute lymphoblastic leukemias. Leukemia 1996:10(2):255-60.
Cayuela JM, Hebert J, Sigaux F. Homozygous MTS1 (p16INK4A) deletion in primary tumor cells of 163 leukemic patients. Blood 1995;85(3):854.
Cayuela JM, Madani A, Sanhes L, Stern MH, Sigaux F. Multi- ple tumor-suppressor gene 1 inactivation is the most frequent genetic alteration in T-cell acute lymphoblastic leukemia. Blood 1996:87(6):2180-6.
Hayette S, Thomas X, Bertrand Y, et al. Molecular analysis of cyclin-dependent kinase inhibitors in human leukemias. Leukemia 1997;11(10):1696-9.
Nakao M, Yokota S, Kaneko H, et al. Alterations of CDKN2 gene structure in childhood acute lymphoblastic leukemia: mu- tations of CDKN2 are observed preferentially in T lineage. Leukemia 1996;10(2):249-54.
Ogawa S, Hangaishi A, Miyawaki S, et al. Loss of the cyclin- dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies. Blood 1995;86(4):1548-56.
Quesnel B, Preudhomme C, Philippe N, et al. p16 gene ho- mozygous deletions in acute lymphoblastic leukemia. Blood 1995;85(3):657-63.
Rubnitz JE, Behm FG, Pui CH, et al. Genetic studies of child- hood acute lymphoblastic leukemia with emphasis on p16, MLL, and ETV6 gene abnormalities: results of St Jude Total Therapy Study XII. Leukemia 1997;11(8):1201-6.
Okuda T, Shurtleff SA, Valentine MB, et al. Frequent deletion of p16INK4a/MTS1 and p15INK4b/MTS2 in pediatric acute lymphoblastic leukemia. Blood 1995;85(9):2321-30.
Brenner MK, Pinkel D. Cure of leukemia. Semin Hematol 1999;36(4 Suppl 7):73-83.
Schröder M, Mathieu U, Dreyling MH, et al. CDKN2 gene deletion is not found in chronic lymphoid leukaemias of B- and T-cell origin but is frequent in acute lymphoblastic leukae- mia. Br J Haematol 1995;91(4):865-70.
Kees UR, Burton PR, Lü C, Baker DL. Homozygous deletion of the p16/MTS1 gene in pediatric acute lymphoblastic leukemia is associated with unfavorable clinical outcome. Blood 1997;89(11):4161-6.
Michaelides K, Schwaab R, Lalloz MRA, Schmidt W, Tuddenham JL. Mutational analysis: New mutations. In: McPherson MJ, Hames BD, Taylor GR, editors. PCR 2: A practical approach. Oxford: Oxford University Press; 1995.p257-88.
Washimi O, Nagatake M, Osada H, et al. In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non- small cell lung cancers. Cancer Res 1995;55(3):514-7.
Okamoto A, Hussain SP, Hagiwara K, et al. Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res 1995;55(7):1448-51.
Yoshida S, Todoroki T, Ichikawa Y, et al. Mutations of p16Ink4/ CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers. Cancer Res 1995;55(13):2756-60.
Volm M, Koomägi R, Stammler G, Rittgen W, Zintl F, Sauerbrey
A. Prognostic implications of cyclins (D1, E, A), cyclin-depend- ent kinases (CDK2, CDK4) and tumor-suppressor genes (pRB, p16INK4A) in childhood acute lymphoblastic leukemia. Int J Cancer 1997;74(5):508-12.
